Additionally, the Bcl2-inhibitor venetoclax (VEN) is particularly effective in IDH2mutAML as the accumulation of the oncometabolite 2-HG inhibits cytochrome C oxidase and effectively primes AML blasts to Bcl2 inhibition. The gene discussed is BCL2; the disease is acute myeloid leukemia.